A

Alcon

Eye care products and vision solutions

Principal I - Research & Development Quality Assurance, T

Full-TimeUpdated Deadline 11/30/26
No salary listed
Mid, Senior, Expert
Bachelor's
Bengaluru, Karnataka, India
In PersonRelocation assistance available; must be willing to work IST time zone.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Bachelor’s degree in engineering, computer science, life sciences, or a related field
  • 5+ years relevant experience.
  • Experience in software QA or validation within a regulated environment
  • Working knowledge of CSV, CSA, and 21 CFR Part 11
  • Experience performing change control and impact assessments
  • Experience supporting GxP systems
  • Experience working in an ISO 13485 medical device environment
  • Familiarity with Agile development environments
  • Ability to work effectively with global, cross functional teams
Responsibilities
  • Provide QA oversight for Digital Health software tools and customer-facing supporting software systems and infrastructure
  • Apply CSV and CSA risk-based approaches to review and assess validation and testing strategies
  • Perform GxP and impact assessments to help determine validation scope and testing needs
  • Assess and support change control activities, including validation and risk impact assessments
  • Ensure systems remain in a validated state throughout their lifecycle through oversight and governance
  • Integrate QA and validation oversight activities into Agile sprints and releases
  • Review requirements and user stories for quality, testability, and traceability
  • Review and approve testing evidence, defect assessments, and retesting outcomes as appropriate
  • Collaborate with IT and development teams to support compliant system delivery
  • Support audit and inspection readiness activities as needed
  • Provides strategic guidance for post-market support activities
  • Operates independently on complex tasks and contributes to critical QA technical decisions.
Desired Qualifications
  • Experience supporting systems used in IT development or cloud operations
  • Familiarity with Agile tools such as Jira or ServiceNow
  • Experience supporting audits or regulatory inspections
  • Strong communication and collaboration skills

About the company

Alcon provides eye care products and vision solutions to improve how people see. It develops and manufactures devices and consumables for eye health, including cataract surgery equipment and intraocular lenses, retinal health therapies, and contact lenses, distributed through eye care professionals, hospitals, and consumers. The products work by supporting eye surgery, protecting and restoring vision, or correcting vision with lens-based options, backed by research and development and a global distribution network. Alcon differentiates itself with a broad, end-to-end portfolio across the eye care continuum, a strong emphasis on research and development, strategic partnerships with healthcare providers, and a commitment to diversity and inclusion. Its goal is to enhance vision and quality of life by delivering reliable, high-quality eye care solutions and advancing the science of eye health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Geneva, Switzerland

Founded

1945

Get referred to Alcon

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Systane PRO PF launched in Canada on September 28, 2026, extending premium dry-eye pricing.
  • UNITY CS and UNITY M shipped in September 2026, expanding Alcon's installed base.
  • Q2 2026 sales rose 8%, while core EPS grew 11% and cash generation stayed strong.

What critics are saying

  • Alcon discontinued PowerVision IOLs in August 2026 after unpredictable postoperative vision outcomes.
  • Implantables grew only 1% constant currency in Q2 2026, signaling cataract competition.
  • If UNITY adoption slows, Alcon depends on mature cataract tools and Systane cash flow.

What makes Alcon unique

  • Alcon's UNITY surgical platform integrates cataract, vitreoretinal, and microscope workflows across 2026 launches.
  • Systane's preservative-free dry-eye franchise leads global artificial tears and deepens consumer reach.
  • Alcon sells across 140 countries, balancing surgical devices with recurring vision-care consumables.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental, & vision coverage
  • HSA Medical Plan
  • PTO
  • Paid Parental leave
  • 401k
  • Retirement Plan Company Contribution
  • Low payroll deductions
  • Tuition Reimbursement Program
  • Annual Bonus
  • Free Family Contact Lens Program
  • 12 Company Paid Holidays

Growth & Insights and Company News

6 month growth

4%

1 year growth

16%

2 year growth

16%
Fort Worth Report
Oct 30th, 2026
Bob on Business: Do you love Fort Worth? The rest of the world does too.

Bob on Business: Do you love Fort Worth? The rest of the world does too. by Bob Francis October 30, 2026 6:28 pm Enjoy reading the news again. Join over 110,000 neighbors who count on our newsletters for stories happening in your backyard. Sign up for free. "Fort Worth, I Love You," was once a locally popular Michael Martin Murphy tune in the early days of outlaw country music. The world has now opened their hymn book to sing along to that tune as well. The rest of the world may not get a red and blue tattoo on their bicep saying such, as the character in the song does, but they are putting their money where their mouth is to the tune of $1.9 billion in new capital investment so far this year, creating 4,100 new jobs. Those numbers can seem overwhelming, but Robert Allen, president and CEO of the Fort Worth Economic Development Partnership can break it down for you. "To put that into perspective, that is more than $5 million in new investment and more than 11 new jobs created every day in Fort Worth," he said. "The growth is real and the growth is for all of our community, not some of it. In a word, Fort Worth has momentum," Allen said at the privately funded nonprofit's annual event Thursday at the Hotel Drover. In 2026, the Fort Worth Economic Development Partnership managed more than 180 inbound projects and inquiries, including 13 wins and seven more in their final stages, Allen said. Project activity increased most in aerospace and defense, advanced manufacturing and corporate operations, he said. And the companies are coming from all over the world: Taiwan, Germany and Australia, to name a few of the new accents you may hear around town. Fort Worth now has the economic development skins on the wall to prove they are serious about doing business. It's not just those outside the area though that are putting down roots where the West begins. Allen pointed to Fort Worth's own Alcon which is investing $186 million to add two manufacturing lines at its campus here that will create 241 new jobs. The Fort Worth Economic Development Partnership was created in 2023, spun off from the Fort Worth Chamber of Commerce, to put some fuel on the city's economic development embers. That fuel seems to have caught fire. "Our inbound pipeline isn't just getting bigger, it's getting better," he said. "We have seen aerospace and defense projects double in volume from the previous year." The partnership is also seeing big increases in advanced manufacturing and corporate operations. "Our pipeline is more diverse than it's ever been," he said. Company timelines are shrinking in terms of how quickly they move from considering a site to making a decision, Allen said. "Companies are making location decisions faster than ever, and the ability to execute with speed and certainty now may determine whether a project happens at all," he said. The number of wins for the city shows that the Fort Worth economic development team can operate in this environment by moving quickly and efficiently. Even though the organization has only been around for about 2 1/2 years, Allen said he has seen a shift in the perception of Fort Worth. Since its beginning, the organization has seen the city receive $11.6 billion in capital investment and add 15,100 jobs. "Companies are calling on us, they are seeking us out," he told the Fort Worth Report. "That is all great. But we've still got to be diligent, still got to be at the top of our game. We still have to execute." But, he said, "momentum matters. Companies see other companies investing here. They see job growth. They see a city that's serious about its economic future." More economic wins... Two days after the Fort Worth City Council approved a package of incentives, Nvidia supplier King Yuan Electronics' subsidiary, AeternZ Semiconductor Testing, confirmed in a filing with the Taiwan Stock Exchange on Oct. 29 that it has purchased land and buildings in Fort Worth for $79.4 million. The project would be the company's first U.S. manufacturing facility. The property, at 273 W. Everman Parkway, includes 1.18 million square feet and about 489,500 square feet of buildings. It would be the largest investment to date in the Interstate 35W South corridor, according to a presentation to the city council by the Fort Worth Economic Development Department. At an Oct. 27 meeting, city council unanimously approved a 10-year tax abatement agreement for up to 65% of city taxes for AeternZ Semiconductor. The incentives have an estimated value of $50 million. The new plant is expected to generate about $26.8 million in new taxes over the term of the agreement. To receive the tax abatement, the company would have to have made a minimum capital investment of $1.3 billion by December 2028, split between $1 billion in real property improvements and $300 million in business equipment, according to the council presentation. AeternZ Semiconductor would also be required to have hired 630 full-time employees with a minimum average salary of $80,000, with an estimated annual payroll of $50 million. The company started construction on a part of the $300 million project that involves renovating and expanding a 500,000-square-foot building, according to a filing on the Texas Department of Licensing and Regulation site made on Oct. 28. Construction should be completed by August 2027. AeternZ Semiconductor is a subsidiary of Taiwan's King Yuan Electronics Co., which has over 9,500 employees and has annual revenues of $1.02 billion. King Yuan is a supplier to chip maker Nvidia and other semiconductor manufacturers, providing wafer probing, final product test and assembly service for the semiconductor back-end supply chain. According to Reuters, the company announced in June it was planning to invest $1.4 billion in the U.S. to support its growth and strengthen its supply chain. And more on the way... Lighthouse Electric Co., a Pittsburgh-based electrical contracting firm specializing in complex electrical system design is considering Fort Worth for a plant that builds modular electric solutions for off-site manufacturing environments. The city council heard a presentation on the project that could bring 600 jobs with an average annual salary of $91,000 and an investment of $30 million. One other city is competing for the project. Lighthouse established a company, Beacon Modular, to manufacture the product line, which has seen growth in recent years, according to the presentation from the Fort Worth Economic Development Department. The project would be valued at $30 million, with $27 million in business equipment and $3 million in property and improvements. The city would offer Beacon a five-year incentive package with $100,000 in grants, up to $500,000 from the Economic Development Incentives Fund. Beacon Modular is also applying for funds from the Texas Enterprise Fund. The company would have to have $250 million or above in annual taxable sales required to maximize the annual grant at $100,000, according to the presentation. If Fort Worth is selected, the company would operate out of Gateway Alliance 71, 4801 Henrietta Creek, in the AllianceTexas development. Council members will vote on the agreement at their Nov. 10 meeting. Do you have news for Bob on Business? Contact Bob Francis, business editor for the Fort Worth Report, at [email protected]. Disclosure: Hillwood is a contributor to the Fort Worth Report. News decisions are made independently of our board members and financial supporters. Read more about our editorial independence policy here.

Business Wire
Oct 20th, 2026
Alcon buys Neurotech for $550M to add first FDA-approved MacTel therapy

Alcon has acquired Neurotech Pharmaceuticals for $550 million, adding a rare eye disease therapy to its retina portfolio. The Geneva-based eye care company may owe further contingent payments, including on commercial milestones. Neurotech's ENCELTO is the first and only US Food and Drug Administration (FDA) approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The FDA approved it in March 2025, and it is available only in the US. MacTel is a progressive retinal disease that causes irreversible central vision loss. About 25,000 people in the US have been diagnosed, with 2,000-3,000 new cases each year. Alcon expects the deal to be slightly dilutive to core diluted earnings per share in 2027, and accretive after that.

cash.ch
Oct 20th, 2026
Alcon buys Neurotech for 550 million dollars.

Alcon buys Neurotech for 550 million dollars. Alcon has acquired the US biotech company Neurotech Pharmaceuticals. The ophthalmology specialist is paying 550 million dollars for it and could make further performance-related payments, as stated in a statement on Tuesday. 20.10.2026 13:44 With the acquisition, Alcon is expanding its retina business with Encelto. The drug is the first and only approved treatment in the US for adults with MacTel type 2, a rare retinal disease with progressive loss of central vision. The US drug regulator approved Encelto in March 2025. In the US, according to Alcon, there are around 25,000 diagnosed MacTel patients. Between 2,000 and 3,000 new diagnoses are added each year. Neurotech develops cell therapies for chronic and neurodegenerative eye diseases. The company works with an encapsulated cell therapy intended to release therapeutic proteins in the eye over the long term. Alcon expects the acquisition to slightly increase revenue growth in 2027 and slightly weigh on adjusted earnings per share. Thereafter, the acquisition should be earnings-accretive. awp-robot/rw

Associated Press
Oct 16th, 2026
FDA approves Alcon's Brytly eye drops, lasting up to 50% longer than Lumify

Alcon said the US Food and Drug Administration (FDA) has approved BRYTLY Redness Reliever Eye Drops, a new over-the-counter product for eye redness. The Geneva-based eye care company announced the approval on October 16, 2026. One drop works in a minute and lasts up to 12 hours, Alcon said. Based on label claims, that is up to 50% longer than Lumify, which lasts up to eight hours. BRYTLY contains no bleaches or dyes. Studies showed a low risk of redness rebound when used as directed. "This FDA approval marks an exciting milestone for Alcon," said Jonathan Balch, general manager of Ocular Health & Pharmaceuticals. The drops should reach major US retailers and online stores in the coming months, with other markets to follow.

AD HOC NEWS
Oct 16th, 2026
RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17.

RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17. Published on 10/16/2026 at 03:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS The October 15, 2026 deal pairs RxSight's adjustable lens technology with Alcon's designs. Twelve firms assign RxSight stock a USD 8.17 consensus target. Collaboration and financial pressure. * RxSight and Alcon agreed on a collaboration worth up to USD 200 million on October 15, 2026. * Second-quarter revenue reached USD 33.7 million, while product sales totaled USD 27.2 million. * Twelve firms assign RxSight a USD 8.17 consensus target. * MarketBeat estimates the next results date as November 4, 2026. * RxSight had a USD 194.2 million market capitalization as of October 15, 2026. RxSight (ISIN US78349D1072) and Alcon announced a non-exclusive collaboration on October 15, 2026, to develop adjustable presbyopia-correcting intraocular lenses with up to USD 200 million in upfront and milestone payments, according to Latham and Watkins. The agreement combines RxSight's post-operative light-adjustable technology with Alcon's optical designs. Discover more Invest in Stocks What does the Alcon deal add? The collaboration gives RxSight a route into presbyopia-correcting lenses while its existing platform remains centered on cataract surgery. The company recognized USD 6.5 million of collaboration revenue in the second quarter of 2026, and its June 30, 2026 balance sheet included USD 208.8 million in cash, cash equivalents and short-term investments, according to RxSight. Why margins still matter. RxSight reported USD 33.7 million of revenue in the second quarter of 2026, including the Alcon contribution, compared with USD 33.6 million in the year-ago quarter. Product sales fell 19 percent year over year to USD 27.2 million, while gross margin excluding collaboration revenue declined to 71.2 percent from 74.9 percent, according to RxSight. The company posted a GAAP net loss of USD 12.1 million, or USD 0.29 per diluted share, for that period. Analyst sentiment remains cautious. MarketBeat reported on October 3, 2026, that twelve firms assigned an average Reduce rating and a USD 8.17 12-month target. The group included three sell ratings, seven hold ratings and two buy ratings. When does RxSight report again? MarketBeat estimates that RxSight will report third-quarter 2026 results on November 4, 2026, after the market closes. The estimate puts the next report at the center of the debate over product demand, collaboration revenue and operating costs. Discover more Stock market analysis NASDAQ stock quotes Eye health blog Stock valuation and next catalyst. RxSight's latest Nasdaq quote was USD 4.67 on October 15, 2026 at 4:00 p.m. ET. The stock had a USD 194.2 million market capitalization and a 52-week range of USD 4.40 to USD 16.74 as of that date. The next reported figures will show whether the Alcon collaboration can offset weaker product sales. RxSight key facts. * Company: RxSight, Inc. * ISIN: US78349D1072 * Ticker: RXST * Primary exchange: Nasdaq * Primary quote: USD 4.67 on October 15, 2026 at 4:00 p.m. ET * Market capitalization: USD 194.2 million (as of October 15, 2026) * 52-week range: USD 4.40-16.74 (as of October 15, 2026) * Sector / Industry: Healthcare / Medical Devices Sponsored Ad Discover more Order Contacts Source Med Gear Find Vision Aids Rxsight stock: new analysis - 21 October. Fresh Rxsight information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US78349D1072 | RXST | boerse | 70334533 | bgmi